Abstract
Family-based studies provide a unique opportunity to characterize genetic risks of diseases in the presence of population structure, assortative mating, and indirect genetic effects. We propose a novel framework, PGS-TRI, for the analysis of polygenic scores (PGS) in case-parent trio studies for estimation of the risk of an index condition associated with direct effects of inherited PGS, indirect effects of parental PGS, and gene-environment interactions. Extensive simulation studies demonstrate the robustness of PGS-TRI in the presence of complex population structure and assortative mating compared to alternative methods. We apply PGS-TRI to multi-ancestry trio studies of autism spectrum disorders (Ntrio = 1,517) and orofacial clefts (Ntrio = 1,904) to establish the first transmission-based estimates of risk associated with pre-defined PGS for these conditions and other related traits. For both conditions, we further explored offspring risk associated with polygenic gene-environment interactions, and direct and indirect effects of genetically predicted levels of gene expression and metabolite traits.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Drs. Wang and Chatterjee were supported by the National Institutes of Health (NIH) grant 1R01HG010480-01. Dr. Wang was also supported by 1K99HG013674-01. The research of Dr. Chatterjee was also supported by U01CA249866, U01HG011719, and 1U24OD023382-01. The GEARS project and Drs. Volk and Ladd-Acosta were supported by funding from R01ES034554 for this work. Dr. Ray was supported by R35GM150836. Drs. Beaty and Ruczinski were supported by NIDCR R01DE031855.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located in dbGaP at https://www.ncbi.nlm.nih.gov through dbGaP accession number phs000094.v1.p1. Approved researchers can obtain the SPARK population dataset described in this study by applying at https://base.sfari.org. We appreciate obtaining access to recruit participants through SPARK research match on SFARI Base.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
